About us Contacts Drug interactions: 390 212
Drug search by name

Actos and Humalog

Determining the interaction of Actos and Humalog and the possibility of their joint administration.

Check result:
Actos <> Humalog
Relevance: 12.08.2022 Reviewer: Shkutko P.M., M.D., in

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Consumer:

Using pioglitazone together with insulin lispro may increase the risk and/or severity of side effects such as hypoglycemia (low blood sugar), fluid retention, swelling, and possibly heart failure. Talk to your doctor if you have any questions or concerns. You may need a dose adjustment or more frequent monitoring by your doctor to safely use both medications. Contact your doctor if you experience hypoglycemia, symptoms of which may include headache, dizziness, drowsiness, nervousness, confusion, tremor, nausea, hunger, weakness, perspiration, palpitation, and rapid heartbeat. Also seek medical attention if you develop sudden, unexplained weight gain; swelling of the hands, ankles, or feet; chest pain; or difficulty breathing during treatment with these medications. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor..

Professional:

MONITOR: Coadministration of a thiazolidinedione in combination with insulin may increase the risk of edema compared to insulin alone. The mechanism is unknown but may involve enhancement of the antinatriuretic and/or peripheral vasodilatory effects of insulin. In a study of 319 type 2 diabetic patients inadequately controlled on twice-daily insulin monotherapy, edema occurred in 13.1% and 16.2% of the patients coadministered rosiglitazone 4 mg/day and 8 mg/day, respectively, compared to 4.7% of those coadministered a matching placebo. Small but statistically significant decreases in hemoglobin and hematocrit were also observed with rosiglitazone compared to placebo. These events were classified as mild to moderate and not considered serious. In a similar study involving 566 patients on stable insulin monotherapy, mild or moderate edema occurred in 12.6% and 17.6% of patients who received pioglitazone 15 mg/day and 30 mg/day, respectively, compared to 7.0% of those who received placebo. Additionally, mild or moderate hypoglycemia occurred in 8% and 15% of patients who received pioglitazone 15 mg/day and 30 mg/day, respectively, compared to 5.0% of those who received placebo. Also, mean change from baseline body weight was 2.3 kg for the 15 mg pioglitazone group and 3.7 kg for the 30 mg pioglitazone group, whereas no change occurred in the placebo group. In a retrospective study of 79 patients who were initially on a thiazolidinedione or insulin separately but were subsequently given both in combination, 20 patients (25.3%) developed edema during the combination, compared to 7 of 71 patients (9.9%) during insulin alone and 1 of 8 patients (12.5%) during thiazolidinedione alone. The mean time to onset of edema was 135 days once combination therapy was initiated. There was no documentation of new-onset or exacerbation of congestive heart failure during combination therapy. However, one patient developed flash pulmonary edema after 2 months of combination therapy and died.

MANAGEMENT: Caution is advised during coadministration of thiazolidinedione and insulin therapy. Patients at risk for heart failure should be closely monitored. Patients should be advised to notify their physician immediately if they experience signs and symptoms of heart failure such as fluid retention, edema, rapid weight gain, or shortness of breath. Patients should also be apprised of the increased risk of hypoglycemia and be alert to potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nausea, hunger, tremor, weakness, sweating, palpitations.

References
  • King KA, Levi VE "Prevalence of edema in patients receiving combination therapy with insulin and thiazolidinedione." Am J Health Syst Pharm 61 (2004): 390-3
  • Raskin P, Rendell M, Riddle MC, Dole JF, Freed MI, Rosenstock J "A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes." Diabetes Care 24 (2001): 1226-32
  • Rosenstock J, Einhorn D, Hershon K, Glazer NB "Efficacy and safety of pioglitazone in type 2 diabetes: a randomised, placebo-controlled study in patients receiving stable insulin therapy." Int J Clin Pract 56 (2002): 251-7
Actos

Generic Name: pioglitazone

Brand name: Actos

Synonyms: n.a.

Humalog

Generic Name: insulin lispro

Brand name: Admelog, Humalog, Humalog, HumaLOG Pen, HumaLOG KwikPen, HumaLOG Cartridge, HumaLOG Junior KwikPen, Admelog SoloStar

Synonyms: n.a.

In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.

Interaction with food and lifestyle
Disease interaction